Skip to main content
Top
Published in: Annals of Hematology 2/2013

01-02-2013 | Original Article

Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K–562 with unmodified or chemically modified siRNAs and induction of apoptosis

Published in: Annals of Hematology | Issue 2/2013

Login to get access

Abstract

Signal transducers and activators of transcription (STAT) proteins are latent cytoplasmic transcription factors that affect several cellular processes including cell growth, proliferation, differentiation, and survival. Following phosphorylation, STATs are activated, and their upregulated expressions increase in malignancies with playing a role in the development of leukemia. In this study, transfection of K–562 cells with either unmodified or chemically modified anti-STAT3, -STAT5A, -STAT5B siRNAs for duration of 12 days, determining gene silencing at mRNA and protein levels, evaluating apoptosis rate, and detecting JAK/STAT pathway members’ gene expression profiles via array method were aimed. Quantitative RT-PCR and Western blot assays indicated that STAT expressions were downregulated both at mRNA and protein levels, and TUNEL assay showed that leukemic cell apoptosis was induced due to inhibition of STATs. Array analysis resulted with decreases in signal transducer, phosphorylation inducer, and oncogene expressions, whereas increased expressions in STAT inhibitor and apoptosis inducer genes were observed. These results point out that siRNA application could constitute a new and alternative curative method for supporting therapy of CML-diagnosed patients in the future.
Appendix
Available only for authorised users
Literature
1.
go back to reference Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematol Am Soc Hematol Educ Program 1:132–152CrossRef Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematol Am Soc Hematol Educ Program 1:132–152CrossRef
2.
go back to reference Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M (2000) Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies. Hematol Am Soc Hematol Educ Program 1:90–109 Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M (2000) Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies. Hematol Am Soc Hematol Educ Program 1:90–109
3.
go back to reference Kantarjian H, Talpaz M, Giles F, O'Brien S, Cortes J (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913–923PubMed Kantarjian H, Talpaz M, Giles F, O'Brien S, Cortes J (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913–923PubMed
4.
go back to reference Vaidya S, Ghosh K, Vundinti BR (2011) Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87(5):381–393PubMedCrossRef Vaidya S, Ghosh K, Vundinti BR (2011) Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87(5):381–393PubMedCrossRef
5.
go back to reference Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71(6):713–721PubMedCrossRef Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71(6):713–721PubMedCrossRef
6.
go back to reference Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281–1283PubMedCrossRef Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281–1283PubMedCrossRef
7.
go back to reference Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19(21):2505–2510PubMedCrossRef Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19(21):2505–2510PubMedCrossRef
8.
go back to reference Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 93(15):7673–7678PubMedCrossRef Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 93(15):7673–7678PubMedCrossRef
9.
go back to reference Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4(2):97–105PubMedCrossRef Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4(2):97–105PubMedCrossRef
10.
go back to reference Ilaria RL Jr, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704–31710PubMedCrossRef Ilaria RL Jr, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704–31710PubMedCrossRef
11.
go back to reference Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M (2001) Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97(9):2846–2853PubMedCrossRef Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M (2001) Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97(9):2846–2853PubMedCrossRef
12.
go back to reference Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T (1999) Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189(8):1229–1242PubMedCrossRef Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T (1999) Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189(8):1229–1242PubMedCrossRef
13.
go back to reference Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105–115PubMedCrossRef Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105–115PubMedCrossRef
14.
15.
go back to reference Benekli M, Baumann H, Wetzler M (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27(26):4422–4432PubMedCrossRef Benekli M, Baumann H, Wetzler M (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27(26):4422–4432PubMedCrossRef
16.
go back to reference Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–138PubMedCrossRef Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–138PubMedCrossRef
17.
go back to reference Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9(9):1034–1048PubMedCrossRef Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9(9):1034–1048PubMedCrossRef
18.
19.
go back to reference Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486):1938–1942PubMedCrossRef Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486):1938–1942PubMedCrossRef
20.
go back to reference Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17(1):95–103PubMedCrossRef Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17(1):95–103PubMedCrossRef
21.
go back to reference Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945–954PubMed Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945–954PubMed
22.
go back to reference Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159(10):4720–4728PubMed Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159(10):4720–4728PubMed
23.
go back to reference Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y (2010) Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 51(10):1895–1901PubMedCrossRef Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y (2010) Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 51(10):1895–1901PubMedCrossRef
24.
go back to reference Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T (2003) Chronic myelogenous leukemia molecular signature. Oncogene 22(25):3952–3963PubMedCrossRef Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T (2003) Chronic myelogenous leukemia molecular signature. Oncogene 22(25):3952–3963PubMedCrossRef
25.
go back to reference Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G (2006) Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116(12):3171–3182PubMedCrossRef Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G (2006) Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116(12):3171–3182PubMedCrossRef
26.
go back to reference Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Röhrs S, Romani J, Scherr M, Zaborski M, Drexler HG (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22(12):2169–2175PubMedCrossRef Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Röhrs S, Romani J, Scherr M, Zaborski M, Drexler HG (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22(12):2169–2175PubMedCrossRef
27.
go back to reference Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B (2006) Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107(10):4080–4089PubMedCrossRef Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B (2006) Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107(10):4080–4089PubMedCrossRef
28.
go back to reference Ulger C, Toruner GA, Alkan M, Mohammed M, Damani S, Kang J, Galante A, Aviv H, Soteropoulos P, Tolias PP, Schwalb MN, Dermody JJ (2003) Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet 147(1):28–35PubMedCrossRef Ulger C, Toruner GA, Alkan M, Mohammed M, Damani S, Kang J, Galante A, Aviv H, Soteropoulos P, Tolias PP, Schwalb MN, Dermody JJ (2003) Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet 147(1):28–35PubMedCrossRef
29.
go back to reference Segatto O, Anastasi S, Alemà S (2011) Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 124(11):1785–1793 Segatto O, Anastasi S, Alemà S (2011) Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 124(11):1785–1793
30.
go back to reference Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J 277(23):4814–4827PubMedCrossRef Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J 277(23):4814–4827PubMedCrossRef
Metadata
Title
Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K–562 with unmodified or chemically modified siRNAs and induction of apoptosis
Publication date
01-02-2013
Published in
Annals of Hematology / Issue 2/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1575-2

Other articles of this Issue 2/2013

Annals of Hematology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.